Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities During the current COVID-19 outbreak, the way to manage these diseases remains elusive Limited data is currently available on AID and IS in the context of this new coronavirus infection To date, there is no evidence to support an increase in complications of COVID-19 in these patients In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19 The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak Les patients atteints de maladies autoimmunes (MAI) presentent classiquement un risque accru dinfections, qui est attribue a la maladie en tant que telle, mais aussi aux traitements immunosuppresseurs (IS) et aux comorbidites Durant lepidemie COVID-19, lattitude a adopter par rapport a ces maladies et a leur traitement reste incertaine En effet, les donnees concernant les MAI et lIS dans le cadre de cette nouvelle infection a coronavirus restent encore tres limitees A lheure actuelle, il ny a pas devidence indiquant une augmentation des complications severes en lien avec le COVID-19 chez ces patients De plus, certains medicaments utilises pour traiter les MAI pourraient faire partie de larsenal therapeutique utilise en cas dinfection par le COVID-19 Cet article passe en revue les aspects particuliers des patients souffrant de MAI durant lepidemie COVID-19